MedDay has developed a SPECMET research platform in partnership with Assistance Publique Hopitaux de Paris (APHP) and Commissariat à l’Energie Atomique (CEA) to support the discovery of additional pipeline assets. This platform identifies new therapeutic targets through cerebrospinal fluid metabolomic analysis.
The SPECMET metabolomics platform screens cerebrospinal fluid (CSF) from patients with CNS disorders to identify metabolic pathways that are disrupted. The goal of this approach is to identify approved or shelved compounds that are known to target the aberrant pathway.
- A biobank of 700 CSF samples corresponding to all major neurodegenerative diseases as well as rare inborn errors of metabolism has been constituted in collaboration with Assistance Publique Hôpitaux de Paris (APHP).
- A LC-MS based metabolomics approach has been set up to study approximately 2000 CSF small compounds per CSF sample, including different classes of lipids. This involves close collaboration with the Commissariat à l’Energie Atomique (CEA).
- MedDay has invested in the platform and has exclusive rights for the exploitation of metabolomic signatures.